Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Acute Myeloid Leukemia
63%
Post-transplantation Cyclophosphamide (PTCy)
52%
CD8+ T Cells
38%
Allogeneic Transplant
35%
Clofarabine
35%
Multiple Myeloma
35%
Remission
26%
Overall Survival
25%
Lymphoma
24%
Hematological Malignancies
24%
Relapsed or Refractory Acute Myeloid Leukemia
23%
T-cell chimerism
21%
Patients with Hematological Malignancies
19%
High-dose Chemotherapy
17%
Adult Hematopoietic Stem Cells
17%
Multilineage
17%
Intensive Care
17%
Single Center
17%
Brentuximab Vedotin
17%
Extent of Resection
17%
Leukemia Progression
17%
Hodgkin Lymphoma
17%
Relapsed or Refractory
17%
Occupational Aspirations
17%
Doxycycline
17%
Primary Graft Dysfunction
17%
T Cell Reconstitution
17%
Common Variable Immune Deficiency
17%
Treatment Complications
17%
End-of-life Care
17%
Chimeric Antigen Receptor T-cell Therapy
17%
Confidence Interval
17%
Diffuse Large B-cell Lymphoma (DLBCL)
17%
Retrospective Cohort Study
17%
Functional Impairment
17%
Complication Prevention
17%
Pilot Randomized Controlled Trial
17%
Relative Risk
17%
Marrow Transplantation
17%
Total Body Irradiation
17%
Systematic Meta-analysis
17%
Time Effect
17%
Haploidentical Transplantation
17%
Hematopoietic Stem Cell Transplantation
17%
Haematopoietic Stem Cell Transplant Recipients
17%
Eomesodermin
17%
Glioblastoma
17%
Stem Cell Donor
17%
Educational Needs
17%
Medicine and Dentistry
Transplantation
74%
Acute Myeloid Leukemia
58%
Cyclophosphamide
52%
Hematologic Malignancy
39%
Stem Cell Transplant
39%
Cell Transplantation
35%
Clofarabine
35%
Leukemia Relapse
35%
Hematopoietic Stem Cell Transplantation
28%
Diseases
26%
Overall Survival
22%
Leukemia
22%
Cytopenia
20%
End of Life Care
17%
Cytotoxic T-Cell
17%
Graft Failure
17%
B Cell
17%
Prevalence
17%
Busulfan
17%
Classical Hodgkin Lymphoma
17%
Splenomegaly
17%
Duodenum
17%
Randomized Controlled Trial
17%
Common Variable Immunodeficiency
17%
Complication of Treatment
17%
Whole Body Radiation
17%
Retrospective Cohort Study
17%
Anaplastic Large Cell Lymphoma
17%
Pancreaticoduodenectomy
17%
Liver Dysfunction
17%
Chimeric Antigen Receptor T-Cell Immunotherapy
17%
Breast Implant
17%
Donor Lymphocyte Infusion
17%
Fludarabine
17%
Intensive Care
17%
T-Cell Lymphoma
17%
Rituximab
17%
Cohort Study
17%
Systematic Review
17%
Superior Mesenteric Artery Syndrome
17%
Brentuximab Vedotin
17%
Sensitivity and Specificity
17%
Chimera
17%
Hodgkin's Lymphoma
14%
Diffuse Large B-Cell Lymphoma
13%
Immunity
11%
Symptomatic Treatment
11%
Positron Emission Tomography
11%
Allogeneic Hematopoietic Stem Cell Transplantation
10%